|
Start Date:5/13/2021
Start Time:4:00 PM CDT
Duration:90 minutes
Abstract:
A review of the relapsed / refractory AML treatment landscape, and a presentation of interim Phase 1 clinical data for the Company’s FT516 and FT538 off-the-shelf, iPSC-derived NK cell programs
If you're already registered for the Interim Phase 1 Clinical Data for AML Programs webcast, click below:
ALREADY REGISTERED?
Speakers
$-[WCSpeakerDisplayHTML]-$
|
Interim Phase 1 Clinical Data for AML Programs
Registration Is Closed
|
|
|
|